Printer Friendly

"Trizivir" Approved: Three Existing Drugs in One.

On November 15 the FDA approved Trizivir [R], a product that combines adult doses of three previously approved Glaxo-Wellcome drugs -- AZT, 3TC, and abacavir -- into a single tablet. The rationale is that taking only one tablet twice a day without regard to food may improve adherence in some patients. Some activists are concerned that this treatment might be chosen for institutional convenience (for example when treating prisoners) even when it is not the best medical option for the individual.

The following writeup was released November 15 by the AIDS Treatment Information Service, an agency which provides AIDS treatment information for the U.S. government:

"November 15, 2000: The Food and Drug Administration (FDA) today approved Trizivir for the treatment of HIV in adults and adolescents. Each dose of Trizivir is a fixed-dose combination of Ziagen (abacavir/ABC), Retrovir (zidovudine/AZT), and Epivir (lamivudine/3TC), three nucleoside reverse transcriptase inhibitors (NRTIs) already approved by FDA. Trizivir is not recommended for treatment in adults or adolescents who weigh less than 40 kilograms because it is a fixed-dose tablet.

"Because Trizivir combines a single dose of three drugs into one pill, it may be easier for some patients to comply with their medication regimen. Each component of Trizivir is also available separately. This combination product should only be used by those whose treatment regimens would otherwise include these doses of these three nucleoside analogues. It may be used alone or in combination with other antiretroviral agents for the treatment of HIV infection, but should not be administered concomitantly with abacavir, lamivudine, or zidovudine, which are already contained in Trizivir. The recommended dose is one tablet twice a day.
COPYRIGHT 2000 John S. James
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:AIDS Treatment News
Geographic Code:1USA
Date:Nov 17, 2000
Previous Article:Nevirapine (VIRAMUNE [R]) Strengthens Warning on Liver, Skin Toxicities.
Next Article:Nutrition and HIV Infection: Experience in Zimbabwe: Interview with Lynde Francis.

Related Articles
CPSC Issues NPR for Over the Counter Drugs.
FDA approves Rebif. (News).
Abacavir arm stopped in clinical trial.
Africa: problems getting antiretrovirals for trials.
HIV drugs approved as of August 2003.
One! Two pharmaceutical giants team up to find a simpler, better way to fight HIV.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters